Why the Big Press Is the Wrong First Machine

Almost every first-time buyer we speak to is looking at a machine roughly twice the size they need. The reasoning sounds solid. Buy for where the business is going, not where it is. Avoid replacing the machine in three years.

In solid dose manufacturing that reasoning breaks down, and it breaks down in ways that aren’t obvious from a spec sheet. Here’s why.

A fast press punishes an average granulation

This is the big one and it gets almost no airtime.

At low turret speed, granules have time to flow into the die. Fill is even, weight is stable, and a formulation that isn’t quite right still produces sellable tablets. Speed the turret up and dwell time collapses. Now the granules have milliseconds to fill the die, and any weakness in flow shows up immediately as weight variation, capping and lamination.

A new plant does not have a mature granulation process. It has a formulation that worked in trials and a team learning the equipment. Putting that team behind a high speed double rotary means their learning curve gets paid for in rejected batches, and API is the expensive part of a tablet.

Slower machines are more forgiving. That forgiveness is worth money in year one.

Tooling cost scales with stations

A 16-station turret needs 16 upper punches, 16 lowers and 16 dies for each product. A 45-station turret needs 45 of each. Same product, nearly three times the tooling bill.

Now multiply by the number of products you plan to make. Then add spare tips. Buyers cost the press carefully and then get quietly ambushed by tooling, which for a multi-product plant can approach the price of the machine.

Changeover eats the advantage

Big presses are built for long runs of one product. Their economics assume the machine runs for days without being stripped.

A new Nigerian manufacturer usually has the opposite pattern. Three or four products, modest volumes each, frequent switching. Every switch means stripping the turret, cleaning to a documented standard, refitting tooling, resetting and running trial tablets until weight and hardness are in spec.

On a 45-station machine that’s a long job. Do it twice a week and your 150,000 tablets an hour machine is achieving a fraction of its rating. You’ve bought speed and spent it on cleaning.

Registration is the real bottleneck anyway

Here’s what makes the oversized press genuinely painful. You cannot sell a tablet until that specific product is registered with NAFDAC, and registration takes time regardless of what’s on your factory floor.

So the plant with the huge press and two registered products has exactly the same sales ceiling as the plant with a modest press and two registered products. The extra capacity earns nothing. It just depreciates, insures, occupies floor space and needs its bearings turned over.

Capacity is not the constraint in Nigerian solid dose. Registered products and distribution are.

Validation gets heavier

Every machine has to be qualified and every process validated, and the documentation burden goes up with complexity. More stations, more speed settings, more variables to characterise, more data to generate before you can release commercially.

A small team doing this for the first time on a complicated machine will take longer to reach first commercial batch. That’s months of interest on borrowed money.

Power and the generator

Bigger presses draw more, and they’re rarely the largest load anyway. HVAC usually is. But the press sizing pushes the whole design upward, and every kilowatt of installed load becomes diesel when the grid drops.

Size the generator for the plant you’re running, not the plant you might run. Oversized generators run inefficiently at light load and wet stack.

The counter-argument, because it’s sometimes right

None of this means small is always correct.

If you have a contract manufacturing agreement in hand with committed volumes, buy for that volume. A signed offtake changes the arithmetic completely. If you’re producing a single high-volume product like paracetamol at national scale, long runs are exactly what a big press is for. If you’re targeting ECOWAS export, where Nigeria already accounts for around 60 per cent of regional drug manufacturing, the volume case can be real.

The distinction is whether the demand exists on paper today or in the business plan. Committed volume justifies capacity. Optimism doesn’t.

The practical version

Buy the press that covers your registered products at realistic shift hours, with modest headroom. Get it running, get the granulation stable, get the team competent, get the products registered.

Then buy the second press when the order book demands it. Two mid-size presses beat one large one for a multi-product plant anyway, because you can run one while cleaning the other and you aren’t dead when the single machine goes down.

Redundancy is worth more than rated speed in a country where a single failed part can mean six weeks of waiting.